文献速递胸部肿瘤

肺癌筛查二十年变革:进展与未来方向

A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening.
PubMed 文献 · J Thorac Oncol · 2026-01-01

过去二十年,低剂量CT肺癌筛查成为降低肺癌死亡率最有效策略之一,NLST与NELSON试验显示死亡率降幅超过20%。目前13国已实施国家或区域筛查计划,人工智能、风险预测模型与生物标志物研究正推动筛查精准化与公平可及。

要点

  • NLST与NELSON试验证实LDCT筛查使高危人群肺癌死亡率降幅超过20%。
  • 13国已实施国家或区域肺癌筛查计划,风险预测与AI辅助提升筛查精准度。
  • 将烟草依赖治疗嵌入筛查、推动社区参与和移动筛查可提高筛查覆盖与获益。

核心结论

  • LDCT肺癌筛查已成为高危人群早期检测的标准手段,并持续向精准化、公平可及和多病种早期发现方向演进。

研究设计与样本

  • 本文为综述,汇总NLST和NELSON等里程碑试验及全球肺癌筛查实施进展。

主要发现

  • NLST与NELSON试验显示LDCT筛查使肺癌死亡率降幅超过20%。
  • 目前13个国家已实施国家或区域肺癌筛查计划,更多国家正在筹备推广。
  • 风险预测模型、容积结节评估与结构化管理的进步提高了筛查精准度与效率。
  • 人工智能正在增强结节检测、恶性风险预测、个体化筛查间隔与工作流程优化。
  • 真实世界证据证实筛查改善了分期分布,并提示肺癌死亡率下降。

关键数值与推荐

  • NLST与NELSON试验中LDCT筛查使高危人群肺癌死亡率降幅超过20%。

临床怎么用

  • 在高危人群中使用LDCT进行肺癌筛查,并整合风险预测模型与结构化结节管理流程。
  • 将烟草依赖治疗嵌入肺癌筛查流程,以增加获得的生命年。
  • 通过社区参与、地理空间映射促进公平可及、移动筛查等方式提高筛查参与与持续依从。
  • 关注偶发肺结节项目及从不吸烟人群研究,以扩展早期检测覆盖范围。
  • 利用LDCT机会性评估冠状动脉疾病与慢性阻塞性肺疾病,拓展健康获益。

局限性

  • 本文为综述性文章,未报告原始研究的新增样本量、置信区间或P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the past two decades, lung cancer screening (LCS) with low-dose computed tomography (LDCT) has emerged as one of the most effective strategies for reducing lung cancer mortality. Landmark trials, including NLST and NELSON, demonstrated mortality reductions exceeding 20%, establishing LDCT as the standard of care for early detection in high-risk populations. Currently, 13 countries have implemented national or regional LCS programs, with additional nations preparing for rollout. Advances in risk-prediction models, volumetric nodule assessment, and structured management protocols have improved precision and efficiency. Integration of artificial intelligence is enhancing nodule detection, prediction of malignancy risk, individualized screening intervals, and workflow optimization. Real-world evidence confirms improved stage distribution and suggests reduction in lung cancer mortality. Initiatives such as promoting community engagement, equitable access through geospatial mapping, and mobile screening will improve screening uptake and retention. Embedding tobacco dependence treatment within LCS further augments life-years gained. Complementary incidental pulmonary-nodule programs and expanding studies in people who have never smoked are extending the reach of early detection, whereas biomarker research is progressing toward integration with imaging-based screening. The potential to use LDCT scans to detect coronary heart disease and chronic obstructive pulmonary disease may have a major impact on future health care benefits. Ongoing efforts to harmonize data collection standards, establish quality indicators, and strengthen workforce training are essential to sustain high-quality implementation. As LCS evolves into a cornerstone of lung cancer control, continued innovation in risk stratification, imaging technologies, and biomarker integration will be key to maximizing global benefit and equity.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lam S, Baldwin DR, Devaraj A, et al. A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening. J Thorac Oncol. 2026. PMID: 41651571. doi:10.1016/j.jtho.2025.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。